Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis

Charis Pericleous, Patricia Ruiz-Limón, Zurina Romay-Penabad, Ana Carrera Marín, Acely Garza-Garcia, Lucy Murfitt, Paul C. Driscoll, David S. Latchman, David A. Isenberg, Ian Giles, Yiannis Ioannou, Anisur Rahman, Silvia S. Pierangeli

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective. IgG aPL against domain I of β2-glycoprotein I (β2GPI) [anti-DI (aDI)] is associated with the pathogenesis of APS, an autoimmune disease defined by thrombosis and pregnancy morbidity. To date, however, no study has demonstrated direct pathogenicity of IgG aDI in vivo. In this proof-of-concept study, we designed a novel system to affinity purify polyclonal aDI aPL in order to assess its prothrombotic ability in a well-characterized mouse microcirculation model for APS. Methods. Two polyclonal IgG fractions were isolated from serum of a patient with APS, both with high aPL activity but differing in aDI activity (aDI-rich and aDI-poor). These IgG fractions were tested for their pathogenic ability in an in vivo mouse model of thrombosis. Male CD1 mice were injected intraperitoneally with either aDIrich or aDI-poor IgG; as a control, IgG isolated from healthy serum was used. A pinch injury was applied to the right femoral vein and thrombus dynamics and tissue factor activity in isolated tissue were evaluated. Results. Both aDI-rich and aDI-poor IgG retained aCL and anti-β2GPI activity, while only aDI-rich IgG displayed high aDI activity, as defined by our in-house cut-offs for positivity in each assay. aDI-rich IgG induced significantly larger thrombi in vivo compared with aDI-poor IgG (P<0.0001). Similarly, aDI-rich IgG significantly enhanced the procoagulant activity of carotid artery endothelium and peritoneal macrophages isolated from experimental animals (P<0.01). Conclusion. These data directly demonstrate that the ability to cause thrombosis in vivo is concentrated in the aDI fraction of aPL.

Original languageEnglish (US)
Pages (from-to)722-727
Number of pages6
JournalRheumatology (United Kingdom)
Volume54
Issue number4
DOIs
StatePublished - Dec 11 2014

Fingerprint

Virulence
Anti-Idiotypic Antibodies
Phospholipids
Glycoproteins
Thrombosis
Immunoglobulin G
Antibodies
Femoral Vein
Peritoneal Macrophages
Thromboplastin
Microcirculation
Serum
Carotid Arteries
Autoimmune Diseases
Endothelium
Morbidity
Pregnancy
Wounds and Injuries

Keywords

  • Anti-phospholipid antibodies
  • Anti-phospholipid syndrome
  • Domain i
  • Mouse model
  • Venous thrombosis
  • β2-glycoprotein i

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. / Pericleous, Charis; Ruiz-Limón, Patricia; Romay-Penabad, Zurina; Carrera Marín, Ana; Garza-Garcia, Acely; Murfitt, Lucy; Driscoll, Paul C.; Latchman, David S.; Isenberg, David A.; Giles, Ian; Ioannou, Yiannis; Rahman, Anisur; Pierangeli, Silvia S.

In: Rheumatology (United Kingdom), Vol. 54, No. 4, 11.12.2014, p. 722-727.

Research output: Contribution to journalArticle

Pericleous, C, Ruiz-Limón, P, Romay-Penabad, Z, Carrera Marín, A, Garza-Garcia, A, Murfitt, L, Driscoll, PC, Latchman, DS, Isenberg, DA, Giles, I, Ioannou, Y, Rahman, A & Pierangeli, SS 2014, 'Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis', Rheumatology (United Kingdom), vol. 54, no. 4, pp. 722-727. https://doi.org/10.1093/rheumatology/keu360
Pericleous, Charis ; Ruiz-Limón, Patricia ; Romay-Penabad, Zurina ; Carrera Marín, Ana ; Garza-Garcia, Acely ; Murfitt, Lucy ; Driscoll, Paul C. ; Latchman, David S. ; Isenberg, David A. ; Giles, Ian ; Ioannou, Yiannis ; Rahman, Anisur ; Pierangeli, Silvia S. / Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. In: Rheumatology (United Kingdom). 2014 ; Vol. 54, No. 4. pp. 722-727.
@article{d96df09bbb0b4f8597f464fc67c37a25,
title = "Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis",
abstract = "Objective. IgG aPL against domain I of β2-glycoprotein I (β2GPI) [anti-DI (aDI)] is associated with the pathogenesis of APS, an autoimmune disease defined by thrombosis and pregnancy morbidity. To date, however, no study has demonstrated direct pathogenicity of IgG aDI in vivo. In this proof-of-concept study, we designed a novel system to affinity purify polyclonal aDI aPL in order to assess its prothrombotic ability in a well-characterized mouse microcirculation model for APS. Methods. Two polyclonal IgG fractions were isolated from serum of a patient with APS, both with high aPL activity but differing in aDI activity (aDI-rich and aDI-poor). These IgG fractions were tested for their pathogenic ability in an in vivo mouse model of thrombosis. Male CD1 mice were injected intraperitoneally with either aDIrich or aDI-poor IgG; as a control, IgG isolated from healthy serum was used. A pinch injury was applied to the right femoral vein and thrombus dynamics and tissue factor activity in isolated tissue were evaluated. Results. Both aDI-rich and aDI-poor IgG retained aCL and anti-β2GPI activity, while only aDI-rich IgG displayed high aDI activity, as defined by our in-house cut-offs for positivity in each assay. aDI-rich IgG induced significantly larger thrombi in vivo compared with aDI-poor IgG (P<0.0001). Similarly, aDI-rich IgG significantly enhanced the procoagulant activity of carotid artery endothelium and peritoneal macrophages isolated from experimental animals (P<0.01). Conclusion. These data directly demonstrate that the ability to cause thrombosis in vivo is concentrated in the aDI fraction of aPL.",
keywords = "Anti-phospholipid antibodies, Anti-phospholipid syndrome, Domain i, Mouse model, Venous thrombosis, β2-glycoprotein i",
author = "Charis Pericleous and Patricia Ruiz-Lim{\'o}n and Zurina Romay-Penabad and {Carrera Mar{\'i}n}, Ana and Acely Garza-Garcia and Lucy Murfitt and Driscoll, {Paul C.} and Latchman, {David S.} and Isenberg, {David A.} and Ian Giles and Yiannis Ioannou and Anisur Rahman and Pierangeli, {Silvia S.}",
year = "2014",
month = "12",
day = "11",
doi = "10.1093/rheumatology/keu360",
language = "English (US)",
volume = "54",
pages = "722--727",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis

AU - Pericleous, Charis

AU - Ruiz-Limón, Patricia

AU - Romay-Penabad, Zurina

AU - Carrera Marín, Ana

AU - Garza-Garcia, Acely

AU - Murfitt, Lucy

AU - Driscoll, Paul C.

AU - Latchman, David S.

AU - Isenberg, David A.

AU - Giles, Ian

AU - Ioannou, Yiannis

AU - Rahman, Anisur

AU - Pierangeli, Silvia S.

PY - 2014/12/11

Y1 - 2014/12/11

N2 - Objective. IgG aPL against domain I of β2-glycoprotein I (β2GPI) [anti-DI (aDI)] is associated with the pathogenesis of APS, an autoimmune disease defined by thrombosis and pregnancy morbidity. To date, however, no study has demonstrated direct pathogenicity of IgG aDI in vivo. In this proof-of-concept study, we designed a novel system to affinity purify polyclonal aDI aPL in order to assess its prothrombotic ability in a well-characterized mouse microcirculation model for APS. Methods. Two polyclonal IgG fractions were isolated from serum of a patient with APS, both with high aPL activity but differing in aDI activity (aDI-rich and aDI-poor). These IgG fractions were tested for their pathogenic ability in an in vivo mouse model of thrombosis. Male CD1 mice were injected intraperitoneally with either aDIrich or aDI-poor IgG; as a control, IgG isolated from healthy serum was used. A pinch injury was applied to the right femoral vein and thrombus dynamics and tissue factor activity in isolated tissue were evaluated. Results. Both aDI-rich and aDI-poor IgG retained aCL and anti-β2GPI activity, while only aDI-rich IgG displayed high aDI activity, as defined by our in-house cut-offs for positivity in each assay. aDI-rich IgG induced significantly larger thrombi in vivo compared with aDI-poor IgG (P<0.0001). Similarly, aDI-rich IgG significantly enhanced the procoagulant activity of carotid artery endothelium and peritoneal macrophages isolated from experimental animals (P<0.01). Conclusion. These data directly demonstrate that the ability to cause thrombosis in vivo is concentrated in the aDI fraction of aPL.

AB - Objective. IgG aPL against domain I of β2-glycoprotein I (β2GPI) [anti-DI (aDI)] is associated with the pathogenesis of APS, an autoimmune disease defined by thrombosis and pregnancy morbidity. To date, however, no study has demonstrated direct pathogenicity of IgG aDI in vivo. In this proof-of-concept study, we designed a novel system to affinity purify polyclonal aDI aPL in order to assess its prothrombotic ability in a well-characterized mouse microcirculation model for APS. Methods. Two polyclonal IgG fractions were isolated from serum of a patient with APS, both with high aPL activity but differing in aDI activity (aDI-rich and aDI-poor). These IgG fractions were tested for their pathogenic ability in an in vivo mouse model of thrombosis. Male CD1 mice were injected intraperitoneally with either aDIrich or aDI-poor IgG; as a control, IgG isolated from healthy serum was used. A pinch injury was applied to the right femoral vein and thrombus dynamics and tissue factor activity in isolated tissue were evaluated. Results. Both aDI-rich and aDI-poor IgG retained aCL and anti-β2GPI activity, while only aDI-rich IgG displayed high aDI activity, as defined by our in-house cut-offs for positivity in each assay. aDI-rich IgG induced significantly larger thrombi in vivo compared with aDI-poor IgG (P<0.0001). Similarly, aDI-rich IgG significantly enhanced the procoagulant activity of carotid artery endothelium and peritoneal macrophages isolated from experimental animals (P<0.01). Conclusion. These data directly demonstrate that the ability to cause thrombosis in vivo is concentrated in the aDI fraction of aPL.

KW - Anti-phospholipid antibodies

KW - Anti-phospholipid syndrome

KW - Domain i

KW - Mouse model

KW - Venous thrombosis

KW - β2-glycoprotein i

UR - http://www.scopus.com/inward/record.url?scp=84926465767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926465767&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keu360

DO - 10.1093/rheumatology/keu360

M3 - Article

C2 - 25273993

AN - SCOPUS:84926465767

VL - 54

SP - 722

EP - 727

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 4

ER -